🇺🇸 FDA
Patent

US 11708406

Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11708406 (Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody) held by AVALO THERAPEUTICS, INC. expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
AVALO THERAPEUTICS, INC.
Grant date
Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K31/706, A61K39/3955